In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, the business of anti-aging is valued at about $110 billion and is expected to expand to more than $600 billion within the next four years1. This new obsession with anti-aging is not without good reason; global aging is a concerning phenomenon. The United Nations estimates that by 2050, there will be more than 1.5 billion people aged 65 and over2. As a result, the global incidence and burden of disease of age-related diseases will follow a similar trend. Therefore, the goal of anti-aging research is not solely to extend the human lifespan but to treat or prevent age-related diseases ranging from Alzheimer’s to Parkinson’s to diabetes and cardiovascular diseases, etc. Read More >>